Cytori Projections 2017-2020
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

 
View only
 
 
ABNOPQRSTUVWXYZAAABAC
1
Income Sources
2015 A2016 A2017 E2018 E2019 E2020 EPatients treated in formulas31-Mar-1630-Jun-1630-Sep-1631-Dec-16
2
Japan $ 2,394,000 $ 3,279,000 $ 4,492,230 $ 6,289,122 $ 12,554,771 $ 19,826,679 201820192020 $ 966,000 $ 690,000 $ 575,000 $ 1,048,000 $ 3,279,000
3
general therapies (aesthetics, OA) $ 2,394,000 $ 3,279,000 $ 4,492,230 $ 6,289,122 $ 8,804,771 $ 12,326,679 N/AN/AN/A
4
Urinary Incontinence $ - $ - $ - $ - $ 1,250,000 $ 1,875,000 05075
5
Scleroderma $ - $ - $ - $ 2,500,000 $ 5,625,000 0100225
6
Asia Pacific - including Lorem (all therapies)
$ 787,000 $ 62,000 $ 80,000 $ 125,000 $ 200,000 $ 300,000 $ - $ 6,000 $ 1,000 $ 55,000 $ 62,000
7
Europe $ 675,000 $ 379,000 $ 330,000 $ 1,130,000 $ 20,380,000 $ 23,590,000 $ 132,000 $ 74,000 $ 76,000 $ 97,000 $ 379,000
8
general therapies (aesthetics, OA, IBD, ACL)
$ 595,000 $ 349,000 $ 250,000 $ 350,000 $ 400,000 $ 500,000 4505001,000
9
scleroderma (MAP + Partner) $ 80,000 $ - $ - $ 400,000 $ 3,750,000 $ 6,250,000 8150250
10
ATI-0918 $ - $ - $ - $ - $ 15,000,000 $ 15,000,000
11
Bimini (Puregraft Royalties + Alopecia)
$ - $ 30,000 $ 80,000 $ 380,000 $ 1,230,000 $ 1,840,000 3001,0001,500
12
Americas $ 982,000 $ 936,000 $ 1,145,000 $ 13,660,000 $ 51,175,000 $ 99,400,000 $ 235,000 $ 356,000 $ 79,000 $ 266,000 $ 936,000
13
general therapies (aesthetics, OA) $ 35,000 $ 50,000 $ 50,000 $ 75,000 $ 150,000 $ 175,000 N/AN/AN/A
14
Okyanos/ New Ownership $ 900,000 $ 811,000 $ 1,000,000 $ 1,000,000 $ 1,000,000 $ 1,000,000 N/AN/AN/A
15
Celase GMP (Worthington Biochemical)
$ 5,000 $ 25,000 $ 25,000 $ 25,000 $ 25,000 $ 25,000 N/AN/AN/A
16
ATI-0918 $ - $ - $ - $ - $ 2,000,000 $ 15,000,000
17
Bimini (Puregraft Royalties + Alopecia)
$ 42,000 $ 50,000 $ 70,000 $ 560,000 $ 1,500,000 $ 2,200,000 3001,0001,500
18
Scleroderma $ - $ - $ - $ 12,000,000 $ 37,500,000 $ 75,000,000 2407501,500
19
Thermal burns (BARDA Purchase in 2019)
$ - $ - $ - $ - $ 9,000,000 $ 6,000,000 00300
20
Product Revenues
$ 4,838,000 $ 4,656,000 $ 6,047,230 $ 21,204,122 $ 84,309,771 $ 143,116,679 $ 1,333,000 $ 1,126,000 $ 731,000 $ 1,466,000 $ 4,656,000
21
Cost of Product Revenues
$ 3,186,000 $ 2,715,000 $ 3,205,032 $ 7,421,443 $ 25,292,931 $ 35,779,170
22
Gross Profit $ 1,652,000 $ 1,941,000 $ 2,842,198 $ 13,782,679 $ 59,016,840 $ 107,337,509
23
34.1%41.7%47.0%65.0%70.0%75.0%
24
Development Revenues:
28
Government BARDA Contract and other
$ 6,821,000 $ 6,724,000 $ 6,500,000 $ 12,000,000 $ 20,000,000 $ 10,000,000
29
Total Development Revenues $ 6,821,000 $ 6,724,000 $ 6,500,000 $ 12,000,000 $ 20,000,000 $ 10,000,000
30
Total Revenue $ 11,659,000 $ 11,380,000 $ 12,547,230 $ 33,204,122 $ 104,309,771 $ 153,116,679
31
Operating Expenses:
32
Research and Development $ 19,000,000 $ 16,196,000 $ 19,206,250 $ 23,600,000 $ 31,500,000 $ 24,250,000
33
Sales and Marketing $ 2,662,000 $ 3,611,000 $ 4,400,000 $ 5,000,000 $ 8,000,000 $ 10,000,000
34
General and Administrative $ 9,765,000 $ 8,564,000 $ 12,000,000 $ 13,000,000 $ 13,000,000 $ 13,000,000
38
Total Operating Expenses $ 23,759,000 $ 28,371,000 $ 35,606,250 $ 41,600,000 $ 52,500,000 $ 47,250,000
39
Operating Gain (Loss) $ (15,286,000) $ (19,706,000) $ (26,264,052) $ (15,817,321) $ 26,516,840 $ 70,087,509
40
Other Income (expense):
44
Interest Income $ 9,000 $ 21,000 $ 3,500 $ - $ 50,000 $ 300,000
45
Interest Expense $ (3,379,000) $ (2,591,000) $ (2,348,000) $ (1,300,000) $ (450,000) $ -
46
Other Income (Expense), net $ (88,000) $ 230,000 $ (100,000) $ (100,000) $ (100,000) $ (100,000)
49
Total Other Income (Expense) $ (3,458,000) $ (2,340,000) $ (2,444,500) $ (1,400,000) $ (500,000) $ 200,000
50
Net Gain (Loss) $ (19,405,000) $ (22,046,000) $ (28,708,552) $ (17,217,321) $ 26,016,840 $ 70,287,509
51
Foreign Currency Translation Adjustments
$ 296,000 $ 262,000
53
Net Comprehensive Gain (Loss)
$ (19,109,000) $ (21,784,000) $ (28,708,552) $ (17,217,321) $ 26,016,840 $ 70,287,509
54
Income Taxes
$ - $ - $ - $ - $ - $ -
55
Net Income After Tax
$ (19,109,000) $ (21,784,000) $ (28,708,552) $ (17,217,321) $ 26,016,840 $ 70,287,509
56
57
Diluted Net Loss per Common Share
$ (2.04) $ (1.26) $ (0.95) $ (0.45) $ 0.66 $ 1.76
58
Fully Diluted Weighted Avg Shares
9,386,488 17,290,933 30,082,890 38,000,000 39,400,000 39,900,000
60
61
Maxim Group: Diluted Net Loss per Common Share
$ (1.34) $ (0.98) $ (0.49) $ 1.38 $ 2.31
62
B. Riley: Diluted Net Loss per Common Share
$ (1.34) $ (0.67) $ (0.10) $ 0.32 $ 0.65
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
Loading...
 
 
 
Company Guidance for 2017
Income Statement
Balance Sheet